Epigenetics impacts upon prognosis and clinical management of choroid plexus tumors

Christian Thomas¹ · Katie Metrock² · Uwe Kordes³ · Martin Hasselblatt¹ · Girish Dhall²

Received: 11 March 2020 / Accepted: 18 April 2020 / Published online: 28 April 2020 © The Author(s) 2020

Abstract

Purpose Choroid plexus tumors comprise of choroid plexus papilloma (CPP, WHO grade I), atypical choroid plexus papilloma (aCPP, WHO grade II) and choroid plexus carcinoma (CPC, WHO grade III). Molecular events driving the majority of choroid plexus tumors remain poorly understood. Recently, DNA methylation profiling has revealed different epigenetic subgroups.

Methods Comprehensive review of epigenetic profiles of choroid plexus tumors in the context of histopathological, genetic, and clinical features.

Summary DNA methylation profiling segregates choroid plexus tumors into three distinct epigenetic subgroups: supratentorial pediatric low-risk choroid plexus tumors (CPP and aCPP), infratentorial adult low-risk choroid plexus tumors (CPP and aCPP), and supratentorial pediatric high-risk choroid plexus tumors (CPP and aCPP and CPC). Epigenetic subgrouping provides additional prognostic information in comparison to histopathological grading.

Conclusions Epigenetic profiling of choroid plexus tumors can be used for the identification of patients at risk of recurrence and is expected to play a role for treatment stratification and patient management in the context of future clinical trials.

Keywords Choroid plexus tumor · TP53 · DNA methylation profiling · 850 k · Copy number alterations · Prognosis · Treatment

Introduction

Choroid plexus tumors are rare neoplasms derived from the choroid plexus epithelium and represent 0.2% of all central nervous system (CNS) neoplasms, but up to 20% of brain tumors arising throughout the first year of life [1]. According to the World Health Organization (WHO) classification, choroid plexus tumors can be divided into choroid plexus papilloma (CPP, WHO grade I), atypical choroid plexus papilloma (aCPP, WHO grade II) and choroid plexus carcinoma (CPC, WHO grade III) [1].

CPP is a benign papillary neoplasm closely resembling non-neoplastic choroid plexus tissue with a single layer of monomorphic epithelial cells covering a highly vascularized stroma. Mitotic activity is absent or very low (< 2 mitoses per 10 high-power fields). CPP has an average annual incidence rate of 0.3 per 1,000,000 and outnumbers CPC by a factor of 5:1 [2, 3]. The median age at diagnosis is four years for CPP and one year for both aCPP and CPC with a majority of patients diagnosed before five years of age [4]. CPPs predominantly arise in the atrium of the lateral ventricle in children [5] and the posterior fossa in adults [6]. Less frequently, CPPs occur in the third ventricle, whereas extraventricular locations (such as the sellar region [7] or brain parenchyma [8]) are exceptional. The majority of patients with CPP experience excellent outcomes following a gross total resection with a 5-year overall survival (OS) rate of 90–100% [9, 10],

Christian Thomas and Katie Metrock have contributed equally.

Martin Hasselblatt
hasselblatt@uni-muenster.de

Girish Dhall
gdhall@peds.uab.edu

¹ Institute of Neuropathology, University Hospital Münster, Münster, Germany
² Division of Pediatric Hematology, Oncology, and Blood & Marrow Transplantation, University of Alabama at Birmingham, Birmingham, USA
³ Department of Pediatric Hematology and Oncology, University Medical Center Hamburg- Eppendorf, Hamburg, Germany
Biology of choroid plexus tumors

Although the majority of choroid plexus tumors occur sporadically, CPCs are strongly associated with Li-Fraumeni syndrome (LFS), a classic cancer predisposition disorder caused by germline mutations of the TP53 tumor suppressor gene [17]. The frequency of TP53 germline mutations in patients with CPC ranges from 26% [18] to 44% [19]. Cases of constitutional mosaicism are also on record [20]. Due to a founder effect, TP53 germ-line mutations (p.R337H) are highly prevalent in southern Brazil (up to 63% of the patients with CPC) [21]. Sanger sequencing of a cohort of 64 choroid plexus tumors revealed somatic TP53 mutations in 50% of CPCs but only 5% of CPPs [19], while other studies reported somewhat lower (36%) [22] or higher (60%) [18] rates of somatic TP53 mutations in CPC. Somatic TP53 mutations or p53 protein accumulation (as a surrogate marker) have been linked to reduced overall and event-free survival in patients with CPC [19]. Also, combining TP53 sequencing results with allele-specific copy-number status of chromosome 17, a higher number of mutated TP53 copies has been associated with a worse outcome [18]. Thus, in a clinical setting, TP53 mutation status may be helpful in risk stratification of CPCs and a thorough family history to rule out Li-Fraumeni syndrome should be obtained. Other rare genetic diseases associated with CPTs include Aicardi syndrome; X-linked genetic disorder characterized by agenesis of the corpus callosum, chorioretinal lacunae, infantile spasms and increased risk of developing (sometimes multifocal) CPPs [23]. Cases of CPP have also been reported in the context of Hyomelanosis of Ito with translocation (X;17) [24] and CPC in a family with Lynch syndrome (hereditary nonpolyposis colorectal cancer) with MSH6 mutation [25]. Despite the known association with genetic syndromes, large scale sequencing studies of CPPs and aCPPs are lacking, and whole genome sequencing (WGS) performed in three TP53-wildtype and one TP53-mutated CPC did not reveal any other recurrent mutation [26].

On a structural level, choroid plexus tumors are characterized by a high degree of chromosomal imbalances. Early cytogenetic analyses have revealed hyperdiploid chromosome sets in CPPs [27, 28] and mainly hypodiploid genomes in CPCs [29, 30]. Using array comparative genomic hybridization (CGH), Rickert et al. have correlated chromosomal imbalances of 34 CPPs and 15 CPCs with clinical follow-up [31]. In that study, gains of chromosome 9p and losses of chromosome 10q were associated with longer survival in CPC. In a more recent study comprising 26 CPCs, loss of chromosome 12q was significantly associated with shorter survival on multivariate analysis, taking into account extent of resection and administration of radiotherapy [32]. Other studies involving larger cohorts confirmed that CPPs and aCPPs are mainly characterized by whole chromosomal gains, whereas CPCs mainly display chromosomal losses [22, 26, 33]. Interestingly, Merino et al. were able to separate CPCs into two distinct groups of hypo- and hyperdiploid CPCs and allele-specific analyses pinpoint that most hyperdiploid CPCs are characterized by acquired uniparental disomy (aUPD) of several chromosomes with chromosome 17 (containing TP53 on 17p13.1) being most affected by this alteration [18]. In summary, chromosomal imbalances are very frequent in choroid plexus tumors, but it remains to be investigated if these alterations are tumor driving events.
Epigenetic subgroups of choroid plexus tumors

Epigenetic dysregulation including alterations of DNA methylation has long been recognized as an important factor contributing to tumorigenesis and tumor maintenance. In particular, specific changes of DNA methylation in small genomic regions were shown to serve as promising targets for the development of powerful prognostic and predictive biomarkers such as MGMT methylation in malignant glioma [34]. On the other hand, global DNA methylation alterations occur due to large somatically acquired changes [35], while retaining characteristics that reflect the cell of origin [36]. Taking advantage of such patterns, methylation-based tumor classification has emerged as a highly robust and reproducible tool even in small biopsies and poor-quality samples to improve diagnostic accuracy and identification of clinically relevant subgroups throughout the last years, including choroid plexus tumors [33, 37, 38]. Merino et al. have shown that CPPs and aCPPs of pediatric patients share epigenetic signatures and segregate from most CPCs on DNA methylation profiling [18]. In another series of 92 choroid plexus comprising 29 CPPs, 32 aCPPs and 31 CPCs of pediatric and adult patients, DNA methylation profiling revealed three epigenetically distinct and clinically relevant subgroups of choroid plexus tumors [18, 33].

As summarized in Table 1, tumors of methylation cluster 1 comprised CPPs and aCPPs characterized by young age and mainly supratentorial location, while methylation cluster 2 comprised mainly infratentorial CPP and aCPPs of adult patients. In contrast, all 31 CPCs clustered with methylation cluster 3 and were characterized by young age and mainly supratentorial location. Importantly, 14 of 32 aCPPs (44%) and 5 of 29 CPPs (17%) shared epigenetic similarities with CPCs and also clustered with methylation cluster 3. The majority of CPPs and aCPPs were encountered within methylation cluster 1 and methylation cluster 2. Both of these clusters differed significantly by age and tumor location. Both methylation clusters also differed on the genetic level, with gains of chromosome 5 and losses of chromosome 21q being more frequently encountered in methylation cluster 2.

While outcome in methylation cluster 1 and methylation cluster 2 was favorable, prognosis of patients in methylation cluster 3 was worse. In this cluster, which contained all CPCs and all p53-positive tumors examined, a total of eight tumor-related deaths occurred, whereas none of the patients in methylation cluster 1 and methylation cluster 2 succumbed to their disease. On multivariate analysis taking into account WHO grade, age, location, copy-number alterations, and p53 status as co-factors, WHO grade (but not methylation clustering) was the only independent predictor of OS whereas the WHO grade and p53 status remained the only predictors of PFS. Analyzing the prognostic role of methylation clustering according to the WHO grade revealed that all recurrences observed in aCPPs occurred in methylation cluster 3, whereas none of the aCPPs of the low-risk clusters (cluster 1 and cluster 2) recurred. Taken together, these data suggest that DNA methylation profiling might be especially useful (and also superior to histopathology) for identifying aCPPs at increased risk of recurrence.

DNA methylation profiling increasingly becomes part of routine neuropathology diagnostics [39] and is available as a web-based platform (www.molecularneuropathology.org). As summarized in Table 1, the CNS Tumor Classifier methylation classes “plexus tumor, subclass pediatric A” and “plexus tumor, subclass pediatric B” correspond to methylation cluster 1 and 3, respectively, whereas “plexus tumor, subclass adult” corresponds to methylation cluster 2. Our database now contains methylation array data of 194 choroid

Table 1 Nomenclature, histopathology and clinical features of epigenetic choroid plexus tumor subgroups

| Designation CNS tumor classifier [37] | Plexus tumor, subclass pediatric A | Plexus tumor, subclass adult | Plexus tumor, subclass pediatric B |
|--------------------------------------|----------------------------------|-------------------------------|----------------------------------|
| Designation in [33]                  | Cluster 1                        | Cluster 2                     | Cluster 3                        |
| Histopathology                       | CPP and aCPP                     | CPP and aCPP                  | CPP, aCPP and CPC                |
| Age group                            | Pediatric                        | Adult                         | Pediatric                        |
| Tumor location                       | Supratentorial                   | Infratentorial                | Supratentorial                   |
| Clinical outcome                     | Low risk                         | Low risk                      | High risk                        |
plexus tumors (78 CPP, 44 aCPP and 72 CPC). In line with earlier results [33], CPP and aCPP branch into all three methylation classes, while CPC cases are uniformly associated with methylation class pediatric B (Fig. 1), emphasizing that current DNA methylation-based classification is not yet providing additional molecular layers for CPCs. Interestingly, a recent study has suggested that novel subclasses among patients with CPC may emerge [40], but these results will need to be validated in larger cohorts before they can be employed in a clinical setting.

**Treatment and trials**

Treatment of CPTs may include surgery, chemotherapy and radiation. Given the rarity of CPTs, prospective clinical trials have been difficult, and treatment has often been based on results from small case series. Complete surgical resection has been shown to be curative for CPPs as well as aCPPs in most cases with no need for adjuvant therapy [14, 41]. Management of incompletely resected aCPPs is less clear, however infants with aCPP generally have a higher event-free survival than older children with aCPP independent of

---

Fig. 1 Histopathology and epigenetic subgroups in choroid plexus tumors. Riverplot showing DNA methylation-based subgroup assignment for each histological subtype. Epigenetic classification of 194 choroid plexus tumors (78 CPP, 44 aCPP and 72 CPC) showing that CPP and aCPP branch into all three epigenetic subgroups, while CPC cases are uniformly associated with methylation class pediatric B. Numbers represents number of assigned samples (N)
adjuvant therapy, hence therapy de-escalation may be warranted in low-risk subgroups.

While complete surgical resection is usually curative in CPPs, the best treatment modalities for CPC remain elusive and the prognosis remains poor. Complete surgical resection is desirable in CPC and has been shown to improve survival but is difficult to achieve upfront due to its infiltrative nature and high vascularity. Radiation therapy has been shown to be effective in the treatment of completely resected CPC patients [42] with 5-year PFS of 68% for patients having received irradiation compared to 16% for patients who did not. However, given the fact that the median age at diagnosis for CPC patients is 12 months with >50% of tumors arising in the supratentorial location, a significant number associated with metastatic disease, and 50% of cases harboring a TP53 mutation, use of craniospinal irradiation would result not only in significant long-term neurocognitive and neuroendocrine sequelae but also an increased risk for secondary neoplasms.

Due to the small number of patients enrolled on infant protocols with CPC, there is limited data; however, chemotherapy does appear to have a beneficial effect in most series. Multiple clinical trials have used either conventional-dose or high-dose chemotherapy in infants and young children with malignant brain tumors with an attempt to either avoid or delay radiation therapy. One of the initial trials using conventional-dose chemotherapy was conducted by the Pediatric Oncology Group (POG), deemed “Baby POG,” that opened in 1986 [43]. Five CPC patients were enrolled on that study; however, survival data were not presented. Children’s Cancer Group study, CCG9921, randomly assigned children <3 years of age with malignant brain tumors between two chemotherapy regimens following surgery with an attempt to delay irradiation. Nine CPC patients were enrolled, of which seven had PD; five within the first year with a 3-year PFS of 33 + 16% and 3-year OS rate of 63 + 17%. UKCCSG/SIOP CNS 9204 trial utilized intensive conventional-dose chemotherapy schedule and included 15 patients with CPC. Eleven of 15 patients progressed on chemotherapy and died with a median time to progression of 0.46 years (range: 0.07–1.13 years). Only two patients had a complete surgical resection. The 5-year OS rate was 26.7% (CI 8.3–49.6) on this study [44]. In the Canadian Pediatric Brain Tumor Consortium experience [13] reported on 16 children <3 years old with CPC, of which 14 had adjuvant conventional dose chemotherapy. Ten of 14 patients developed PD at a median of 10 months with a 5-year OS rate of 31 + 13.2%. The same group also reported on 17 children with CPC treated at a single institution, of which 12 children received adjuvant chemotherapy with ICE (ifosfamide, carboplatin, and etoposide) followed by second-look surgery. The number of cases with gross total resection increased from 2 to 9, resulting in a 5-year PFS and OS of 53 + 16% and 74.1 + 12.9%, respectively, for children treated with a curative intent without irradiation. The first prospective clinical trial for patients with CPTs was CPT-SIOP-2000 study that included maximal surgical resection followed by observation for patients with CPP or completely resected aCPP and adjuvant chemotherapy (etoposide, vincristine, and either carboplatin or cyclophosphamide) for patients with CPC, metastases or incompletely resected aCPP. Patients >3 years old were treated with irradiation after the second cycle of chemotherapy [14]. For 92 of 106 eligible patients (42 with CPP, 30 with aCPP and 34 with CPC) treated according to the study protocol, 5-year EFS and OS probability rates were 92% and 100% for CPP, 83% and 89% for aCPP, and 28% and 36% for CPC patients, respectively.

Intensive induction chemotherapy followed by myelo-suppressive high-dose chemotherapy (HDCTx) and autologous hematopoietic stem cell rescue (AuHCR) is routinely employed to treat infants and young children with malignant brain tumors in order to avoid cranial irradiation. Three sequential “Head Start” (I, II, and III) clinical trials, conducted between 1991 and 2009, enrolled 12 children with CPC and reported 5-year PFS and OS rates of 38% and 62%, respectively, with 5 children surviving irradiation-free at 29, 43, 61, 66, and 89 months from diagnosis. CCG99703, a Children’s Oncology Group study using a similar approach, enrolled four patients with CPC, of which two children were long-term survivors, one of whom had received irradiation at recurrence [45].

In a multi-institutional retrospective analysis, Tabori et al. stratified 36 CPCs by TP53 mutation status and showed that 50% of CPC patients with TP53 mutation had a 5-year OS rate of 0% as compared to 82 + 9% (without irradiation) for CPC patients with TP53 wild-type [19], suggesting that biology of these tumors might have a larger influence on long-term survival rather than the intensity of treatment.

### Summary and future directions

DNA methylation profiling of choroid plexus tumors has revealed three epigenetically distinct and clinically relevant molecular subgroups. Epigenetic profiling will hopefully aid our understanding of choroid plexus tumor biology, can be used for the identification of patients at risk of recurrence and is expected to play an important role for treatment stratification and patient management in the context of future clinical trials. An integrative risk score of age and methylation cluster will be particularly helpful for aCPP. For the LFS cohort of CPC, a large co-operative group trial will have to assess the role of HDCT vs. conventional irradiation-free and alkylator-sparing therapy.
Acknowledgement  Open Access funding provided by Projekt DEAL.
CT is supported by DFG (TH 2345/1–1).

Funding  Funded by Deutsche Forschungsgemeinschaft (TH 2345/1–1).

Compliance with ethical standards

Conflict of interest  The authors declare that they have no conflict of interest.

Ethical approval  This paper does not contain any studies with human participants or animals performed by any of the authors.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Louis DN, Ohgaki H, Wiestler ODCW (2016) World health organization histological classification of tumours of the central nervous system. International Agency for Research on Cancer, France.

2. Rickert CH, Paulus W (2001) Tumors of the choroid plexus. Microsoc Res Tech 52:104–11. https://doi.org/10.1002/1097-0029(20010101)52:1<104::AID-JEMT12>3.0.CO;2-3

3. Jänisch W, Staneczek W (1989) Primary tumors of the choroid plexus. Zentralblatt fur Allg Pathol u Pathol Anat 135:235–240.

4. Lam S, Lin Y, Cherian J et al (2013) Choroid plexus tumors in children. J Neurooncol 115:151–160. https://doi.org/10.1007/s11060-017-2561-2

5. Nagib MG, O’Fallon MT (2000) Lateral ventricle choroid plexus: frequency, localization and age. Zentralbl Pathol 153:235–240.

6. Lam S, Lin Y, Cherian J et al (2013) Choroid plexus tumors in children: a population-based study. Pediatr Neurosurg 49:331–338. https://doi.org/10.1159/000367974

7. Nagib MG, O’Fallon MT (2000) Lateral ventricle choroid plexus papilloma in childhood: management and complications. Surg Neurol 54:366–372. https://doi.org/10.1016/s0090-3019(00)00316-5

8. Saffar M, Oh MC, Sughre ME et al (2013) The relative patient benefit of gross total resection in adult choroid plexus papilomas. J Clin Neurosci 20:808–812. https://doi.org/10.1016/j.jocn.2012.08.003

9. Ma Y-H, Ye K, Zhan R-Y, Wang L-J (2008) Primary choroid plexus papilloma of the sellar region. J Neurooncol 88:51–55. https://doi.org/10.1007/s11060-008-9531-7

10. Qi G, Ni S, Zhou X et al (2015) Extraventricular intraparenchymal choroid plexus tumors in cerebral hemisphere: a series of 6 cases. World Neurosurg 84:1660–1667. https://doi.org/10.1016/j.wneu.2015.07.004

11. Morshed RA, Lau D, Sun PP, Ostling LR (2017) Spinal drop metastasis from a benign fourth ventricular choroid plexus papilloma in a pediatric patient: case report. J Neurosurg Pediatr 20:471–479. https://doi.org/10.3171/2017.5.PEDS17130

12. Jeibmann A, Wrede B, Peters O et al (2007) Malignant progression in choroid plexus papillomas. J Neurosurg 107:199–202. https://doi.org/10.3171/2010.3.PEDS09354

13. Lafay-Cousin L, Mabott DJ, Halliday W et al (2010) Use of ifosfamide, carboplatin, and etoposide chemotherapy in choroid plexus carcinoma. J Neurosurg Pediatr 5:615–621. https://doi.org/10.3171/2010.3.PEDS10010

14. Wrede B, Hasselblatt M, Peters O et al (2009) Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study. J Neurooncol 95:383–392. https://doi.org/10.1007/s11060-009-9936-y

15. Jeibmann A, Hasselblatt M, Gerss J et al (2006) Prognostic implications of atypical histologic features in choroid plexus papilloma. J Neuropathol Exp Neurol 65:1069–1073. https://doi.org/10.1097/01.nen.0000240464.26005.90

16. Thomas C, Ruland V, Kordes U et al (2015) Pediatric atypical choroid plexus papilloma reconsidered: increased mitotic activity is prognostic only in older children. Acta Neuropathol 129:925–927. https://doi.org/10.1007/s00401-015-1434-z

17. Malkin D (2011) Li-fraumeni syndrome. Genes Cancer 2:475–478. https://doi.org/10.1177/194761911143466

18. Merino DM, Shlien A, Villani A et al (2015) Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups. Clin Cancer Res 21:184–192. https://doi.org/10.1158/1078-0432.CCR-14-1324

19. Tabori U, Shlien A, Baskin B et al (2010) TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol 28:1995–2001. https://doi.org/10.1200/JCO.2009.26.8169

20. Trubicka J, Filippek I, Iwanowski P et al (2017) Constitutional mosaicism of a de novo TP53 mutation in a patient with bilateral choroid plexus carcinoma. Cancer Genet 216–217:79–85. https://doi.org/10.1016/j.cancergen.2017.07.001

21. Custodio G, Taques GR, Figueiredo BC et al (2015) High-resolution genomic analysis does not qualify atypical plexus papilloma as a separate entity among choroid plexus tumors. J Neuropathol Exp Neurol 74:110–120. https://doi.org/10.1097/NEN.0000000000001514

22. Aicardi J (2005) Aicardi syndrome. Brain Dev 27:164–171. https://doi.org/10.1016/j.braindev.2003.11.011

23. Japp AS, Gessi M, Messing-ju M et al (2015) High-resolution genomic analysis does not qualify atypical plexus papilloma as a separate entity among choroid plexus tumors. J Neuropathol Exp Neurol 74:110–120. https://doi.org/10.1097/NEN.0000000000001514

24. Sybert VP, Pagon RA (1994) Hypomelanosis of Ito in a girl with plexus papilloma and translocation (X;17). Hum Genet 93:227. https://doi.org/10.1007/bf00210623

25. Zhu VW, Hinduja S, Knezevich SR et al (2017) A rare case of choroid plexus carcinoma that led to the diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer). Clin Neurol Neurosurg 158:46–48. https://doi.org/10.1016/j.clineuro.2017.04.013

26. Tong Y, Merino D, Nimmervoll B et al (2015) Cross-species aberrations in choroid plexus papillomas. Genes Chromosomes Cancer 11:267–270. https://doi.org/10.1002/gcc.2870110410

© Springer
28. Roland B, Pinto A (1996) Hyperdiploid karyotype in a choroid plexus papilloma. Cancer Genet Cytogenet 90:130–131. https://doi.org/10.1016/s0165-4608(96)00091-x
29. Li YS, Fan YS, Armstrong RF (1996) Endoreduplication and telomeric association in a choroid plexus carcinoma. Cancer Genet Cytogenet 87:7–10. https://doi.org/10.1016/10165-4608(95)00234-0
30. Neumann E, Kalousek DK, Norman MG et al (1993) Cytogenetic analysis of 109 pediatric central nervous system tumors. Cancer Genet Cytogenet 71:40–49. https://doi.org/10.1016/10165-4608(93)90200-6
31. Rickert CH, Wiestler OD, Paulus W (2002) Chromosomal imbalances in choroid plexus tumors. Am J Pathol 160:1105–1113. https://doi.org/10.1016/S0002-9440(10)64931-0
32. Ruland V, Hartung S, Kordes U et al (2014) Choroid plexus carcinomas are characterized by complex chromosomal alterations related to patient age and prognosis, Genes Chromosomes Cancer 53:373–380. https://doi.org/10.1002/gcc.22148
33. Thomas C, Sill M, Ruland V et al (2016) Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. Neuro Oncol 18:790–796. https://doi.org/10.1093/neo onc/nov322
34. Dunn J, Baborie A, Alam F et al (2009) Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy, Br J Cancer 101:124–131. https://doi.org/10.1038/sj.bjc.6605127
35. Hovestadt V, Jones DTW, Picelli S et al (2014) Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature 510:537–541. https://doi.org/10.1038/natur eel1268
36. Fernandez AF, Assenov Y, Martin-Subero JI et al (2012) A DNA methylation fingerprint of 1628 human samples. Genome Res 22:407–419. https://doi.org/10.1101/gr.119867.110
37. Capper D, Jones DTW, Sill M et al (2018) DNA methylation-based classification of central nervous system tumours. Nature 555:469–474. https://doi.org/10.1038/nature26000
38. Hovestadt V, Remke M, Kool M et al (2013) Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neupathol 125:913–916. https://doi.org/10.1007/s00401-013-1126-5
39. Capper D, Stichel D, Sahm F et al (2018) Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neupathol 136:181–210. https://doi.org/10.1007/s00401-018-1879-y
40. Pienkowska M, Choufani S, Turinsky AL et al (2019) DNA methylation signature is prognostic of choroid plexus tumor aggressiveness. Clin Epigenetics 11:117. https://doi.org/10.1186/s13148-019-0708-z
41. Kordes UR, Hartung S, Löbel U et al (2018) EMBR-08: choroid plexus tumors in 2018: the cpt-siop experience and long-term outcome. Neuro Oncol 20:i70–i70. https://doi.org/10.1093/neu onc/noy059.192
42. Wolff JE, Sajedi M, Coppes MJ et al (1999) Radiation therapy and survival in choroid plexus carcinoma. Lancet 353:2126. https://doi.org/10.1016/s0140-6736(99)01744-4
43. Duffner PK, Horowitz ME, Krischer JP et al (1999) The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro Oncol 1:152–161. https://doi.org/10.1093/neuo ncr/1.2.152
44. Grundy RG, Wilne SH, Robinson KJ et al (2010) Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial. Eur J Cancer 46:120–133. https://doi.org/10.1016/j.ejca.2009.09.013
45. Cohen BH, Geyer JR, Miller DC et al (2015) Pilot study of intensive chemotherapy with peripheral hematopoietic cell support for children less than 3 years of age with malignant brain tumors, the CCG-99703 phase I/II study. a report from the children’s oncology group. Pediatr Neurol 53:31–46. https://doi.org/10.1016/j.ped neur.2015.03.019

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.